Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care oncology prior auth policy | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization and review

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs requirement for Evolent review/prior authorization of oncology medications and supportive agents for Medicare - Wellcare by Fidelis Care members; affects participating providers dispensing or administering listed drugs in pharmacy, physician office, outpatient hospital, or ambulatory settings.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization and review
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent for review before dispensing or administration; omissions may result in denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~300+HCPCS/CPT/J‑codes and Q codes listed requiring review
    1/1/2026Effective date for Wellcare oral oncology list
    EvolentDesignated reviewer
    Participating providersProvider action required

    Coverage Criteria

    Prior Authorization Requirement

    Covered when ALL of the following are met

    Evolent review required: Request submitted to Evolent for listed oncology medication/supportive agent prior to dispensing or administration

    Applies to pharmacy- and medical-benefit agents listed; clinical trials may be sent to Evolent for review. Requests may be submitted via Evolent web portal or phone as specified by the plan.

    Do NOT submit the following requests to Evolent: Antibiotics; Bone marrow, stem cell transplants and CAR‑T cell therapy; Controlled substances (e.g., morphine); Equipment requests (for example, infusion pumps); Genetic lab testing and laboratory services; Hemophilia drugs; Inpatient drug requests; Inpatient radiation and chemotherapy treatments; Iron preparations; Radiopharmaceuticals; Surgeries/surgical procedures; Sickle cell diagnoses and therapies; and Immune globulins.

    Coding and Effective Dates

    Oncology HCPCS/J codes and Q codes requiring Evolent reviewmixedCovered
    C9293GLUCARPIDASE
    C9307LINVOSELTAMAB-GCPT INJ
    C9308CARBOPLATIN (AVYXA) INJ
    J0185APREPITANT INJ
    J0207AMIFOSTINE INJ
    J0208SODIUM THIOSULFATE
    J0594BUSULFAN INJ
    J0641LEVOLEUCOVORIN INJ
    J0642LEVOLEUCOVORIN INJ
    J0870IMETELSTAT (RYTELO)
    1–10 of 65
    1/7
    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization and review
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent for review before dispensing or administration; omissions may result in denial.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Effective DatesProvider Actions and Submission RequirementsSite of Care RequirementsBiosimilar PreferencesStep Therapy / Preference GuidanceDefinitions / Out of ScopeBackground
    Pharmacy-benefit oral oncology agents (require review)HCPCSCovered
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL
    J8530CYCLOPHOSPHAMIDE ORAL
    J8565GEFITINIB
    J8600MELPHALAN ORAL
    J8999Multiple oral oncology agents listed under J8999 (e.g., ABEMACICLIB, ABIRATERONE, many others)
    inv-05: Effective date
    Effective date (Wellcare by Fidelis Care)1/1/2026
    Applies toPharmacy‑benefit oral oncology agents listed requiring Evolent review
    Reviewer/vendorEvolent (designated reviewer for prior authorization)

    Provider Actions and Submission Requirements

    Prior Authorization

    Evolent review / prior authorization required

    Oncology medications and supportive agents listed in this policy must be submitted to Evolent for review (prior authorization) before being dispensed at a pharmacy or administered in a physician office, outpatient hospital, or ambulatory setting for members of all ages. Clinical trial requests may also be submitted to Evolent for review via the web portal or phone.

    • Submit requests via Evolent Web portal at my.newcenturyhealth.com or call 1-888-999-7713, option 1.
    • Non‑participating providers should submit requests to the plan per the fax number in the source.
    Prior Authorization

    Pharmacy‑benefit oral oncology agents require Evolent review (effective 1/1/2026)

    Specific oral oncology agents listed (e.g., J7520, J7527, J8501, J8530, J8565, J8600, J8655, J8670 and others shown under the pharmacy section) require review by Evolent and will be available via the pharmacy benefit only effective 1/1/2026 for Wellcare by Fidelis Care.

    • See pharmacy‑benefit list in the policy for the full set of oral agents subject to Evolent review and the effective date.
    Step Therapy

    Preferred biosimilars — submit preferred agent to Evolent

    Preferred biosimilar agents are identified for certain oncology therapies; providers should send the preferred biosimilar agents to Evolent for review when requesting authorization.

    • Erythropoiesis‑stimulating agents: medical benefit Retacrit (Epogen if shortage); pharmacy benefit Procrit.
    • Trastuzumab: medical benefit Trazimera (multiple trastuzumab biosimilars listed for pharmacy benefit).
    • Bevacizumab: medical benefit Mvasi, Zirabev (also listed on pharmacy benefit).
    Documentation Required

    Submit the entire oncology regimen to Evolent (portal/phone accepted)

    Submit the entire oncology regimen to Evolent for review rather than individual agents; clinical trial requests may also be submitted via Evolent's portal or phone.

    • Use Evolent Web portal at my.newcenturyhealth.com or call 1-888-999-7713, option 1 to submit requests.
    • Do NOT omit regimen components when submitting — submit the full regimen.
    Denial Risk

    Complete regimen submission required — omission may cause denial

    Omitting portions of the entire oncology regimen when submitting to Evolent may result in a denial.

    • Ensure all agents, supportive medications, and regimen components are included in the single submission to Evolent.

    Site of Care Requirements

    Prior Authorization

    Site-of-care review required prior to dispensing or administration

    Review by Evolent is required before dispensing at a pharmacy or before administration in a physician's office, outpatient hospital, or ambulatory setting.

    • Applies to listed oncology medications and supportive agents for members of all ages

    Biosimilar Preferences

    Billing Rule

    Epoetin alfa / ESA — preferred biosimilar and pharmacy preference

    For erythropoiesis-stimulating agents (ESAs), Retacrit is listed as the preferred medical-benefit biosimilar; Procrit is preferred on the pharmacy benefit.

    • Medical benefit preferred: Retacrit (Epogen if shortage)
    • Pharmacy benefit preferred: Procrit
    Billing Rule

    Trastuzumab (medical benefit) — preferred biosimilar

    For trastuzumab under the medical benefit, Trazimera is identified as the preferred biosimilar; multiple trastuzumab biosimilars are listed as available on the pharmacy benefit.

    • Medical benefit preferred: Trazimera
    • Pharmacy benefit examples: Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera
    Billing Rule

    Bevacizumab — preferred biosimilars

    For bevacizumab under the medical benefit, preferred biosimilars include Mvasi and Zirabev; pharmacy benefit lists Avastin, Mvasi, and Zirabev.

    • Medical benefit preferred: Mvasi, Zirabev
    • Pharmacy benefit examples: Avastin, Mvasi, Zirabev

    Step Therapy / Preference Guidance

    Drug class / referencePreferred agent(s) (benefit)Provider action
    Erythropoiesis‑stimulating agents (Epoetin alfa/ESA)Retacrit (medical benefit; if unavailable due to shortage: Epogen); Procrit (pharmacy benefit)Preferred biosimilar agents identified; providers should send preferred agent selection to Evolent for review
    Trastuzumab (medical benefit)Trazimera (medical benefit); pharmacy benefit options include Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, TrazimeraPreferred biosimilar agents identified; providers should send preferred agent selection to Evolent for review
    BevacizumabMvasi, Zirabev (medical benefit); pharmacy benefit options include Avastin, Mvasi, ZirabevPreferred biosimilar agents identified; providers should send preferred agent selection to Evolent for review
    Hematopoietic agentsZarxio (medical & pharmacy benefit)Preferred biosimilar agents identified; providers should send preferred agent selection to Evolent for review

    Definitions / Out of Scope

    inv-12: Out of scope with Evolent
    Do NOT submit to EvolentAntibiotics; Bone marrow/stem cell transplants and CAR‑T cell therapy; Controlled substances (e.g., morphine); Equipment requests (infusion pumps); Genetic lab testing and laboratory services; Hemophilia drugs; Inpatient drug requests; Inpatient radiation and chemotherapy treatments; Iron preparations; Radiopharmaceuticals; Surgeries/surgical procedures; Sickle cell diagnoses and therapies; Immune globulins.
    Preferred biosimilars guidancePreferred biosimilar agents are listed (e.g., Retacrit/Procrit for ESAs; Trazimera for trastuzumab; Mvasi/Zirabev for bevacizumab) — providers should still send preferred agents to Evolent for review.
    Submission noteSubmit the entire oncology regimen to Evolent; omissions may result in a denial.

    Background

    This policy centralizes clinical review of oncology medications and supportive agents through Evolent to establish medical necessity and determine benefit assignment (medical vs. pharmacy). Participating providers must submit oncology medication requests and supportive agents listed in the policy to Evolent for review prior to dispensing or administration, and the policy identifies preferred biosimilars and items that are out of scope for Evolent review. Additionally, submit the entire oncology regimen to Evolent; omissions may result in a denial.